AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 171 min read$EXPO

Corrigan Catherine sold $109K of EXPO

Corrigan Catherine (Chief Executive Officer) sold 1,737 shares of EXPONENT INC (EXPO) at $62.78 ($0.11M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Corrigan Catherine
Published Jul 17, 2026, 11:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 11:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EXPO
Neutral
high confidence
Mentioned
$EXPO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXPONeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value) and confirmation of a pre-arranged 10b5-1 plan; there is no operational or financial update.

02

Market read

Primarily a sentiment datapoint for EXPO, with limited fundamental implications due to 10b5-1 pre-arrangement.

03

What to watch

Traders may over-weight insider sales; without changes to guidance, contracts, or financial results, the signal is typically weak.

Relevance 3/10Novelty 3/10Timing: after-hours/filing date disclosure on 2026-07-17

Background

The article is a SEC Form 4 insider transaction disclosure for Exponent Inc (EXPO).

Company-level read

Ticker impact

$EXPONeutralHigh confidence
Context

Exponent CEO Corrigan Catherine sold 1,737 shares in an open-market transaction on 2026-07-15 under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any reaction would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly open-market and pre-arranged under a Rule 10b5-1 plan, with no accompanying fundamental news or guidance change.

Market effects

Sector

No clear sector read-through from a single CEO 10b5-1 sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    Exponent Inc

    Company whose CEO filed the Form 4 insider sale disclosure.

  • insider
    Corrigan Catherine

    Exponent CEO and director who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EXPO insider trading history →

Related articles

AUG 8
$EXPOMedAI 8/10

Exponent (EXPO) Q2 2026 Earnings Call Transcript

Exponent, Inc. (EXPO) reported Q2 2026 net revenues of $148.9 million, up 12% from $132.9 million a year earlier, and net income of $29.4 million, up 11%. Diluted EPS was $0.60. Management raised FY 2026 revenue guidance to 9% to 10% growth and EBITDA margin to 27.8% to 28.1%, and authorized an additional $50 million for share repurchases.

fool.com6 min
AUG 1
$EXPOMedAI 8/10

Exponent Q2 Earnings Call Highlights

Exponent (NASDAQ:EXPO) reported Q2 EBITDA up 16% to $42.7 million, with EBITDA margin at 28.7% of net revenue versus 27.8% a year earlier. Billable hours rose 8% to about 390,000 and utilization increased to 74%. The company repurchased $67.4 million of stock and paid $14.8 million in dividends. It raised 2026 outlook for net revenue growth of 9% to 10%.

yahoo.com6 min